BMY News

A Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay $916 million for not warning non-white patients about the health risks of their blood thinner Plavix. The ruling follows a previous $834 million judgment

FDA grants accelerated approval for Bristol Myers Squibb's Breyanzi, a CAR T cell therapy, for relapsed or refractory follicular lymphoma. Breyanzi is included in NCCN guidelines and shows high response rates and sustained clinical benefits in trials.

Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 5.36% since its last report. The company recently reported that it has 22.71 million shares sold short, which is 1.06% of all regular shares that are available for trading.

Pre-open movers U.S. stock futures traded higher in early pre-market trade on Wednesday after recording sharp losses on Tuesday following the release of inflation data for August. All the three major indices settled sharply lower, notching their biggest single-session percentage declines since June 2020.

Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings within the last quarter:

Analysts have provided the following ratings for Bristol-Myers Squibb (NYSE:BMY) within the last quarter:

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Atlantic Equities raised the price target on Bristol-Myers Squibb Company (NYSE: BMY) from $83 to $87. Atlantic Equities analyst Steve Chesney maintained an Overweight rating on the stock. Bristol-Myers Squibb shares rose 6.3% to $74.60 in pre-market trading.

According to Benzinga Pro, during Q1, Bristol-Myers Squibb (NYSE:BMY) earned $1.28 billion, a 45.91% increase from the preceding quarter. Bristol-Myers Squibb's sales decreased to $11.65 billion, a 2.81% change since Q4.

Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings within the last quarter:

The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a measure of innovation in drug research, tapered to merely one for the month.

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Bristol-Myers Squibb (NYSE:BMY) reported its Q1 earnings results on Friday, April 29, 2022 at 06:59 AM. Here's what investors need to know about the announcement.

Bristol Myers Squibb (NYSE: BMY) announced the U.S.

Bristol-Myers Squibb (NYSE:BMY) is set to give its latest quarterly earnings report on Friday, 2022-04-29. Here's what investors need to know before the announcement. Analysts estimate that Bristol-Myers Squibb will report an earnings per share (EPS) of $1.91.